Novan is a pharmaceuticals business based in the US. Novan shares (NOVN) are listed on the NASDAQ and all prices are listed in US Dollars. Novan employs 90 staff and has a trailing 12-month revenue of around $24.9 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.03 |
|---|---|
| 52-week range | $0.02 - $0.04 |
| 50-day moving average | $0.50 |
| 200-day moving average | $1.08 |
| Wall St. target price | $15.50 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.84 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.0347 from 2023-09-26
| 1 week (2024-09-02) | N/A |
|---|---|
| 1 month (2024-08-09) | N/A |
| 3 months (2024-06-09) | N/A |
| 6 months (2024-03-09) | N/A |
| 1 year (2023-09-13) | 28.52% |
|---|---|
| 2 years (2022-09-13) | -98.56% |
| 3 years (2021-09-13) | 8.83 |
| 5 years (2019-09-13) | 27.5 |
| Revenue TTM | $24.9 million |
|---|---|
| Gross profit TTM | $313,000 |
| Return on assets TTM | -25.84% |
| Return on equity TTM | -2098.89% |
| Profit margin | -128.61% |
| Book value | $-0.10 |
| Market Capitalization | $2.6 million |
TTM: trailing 12 months
We're not expecting Novan to pay a dividend over the next 12 months.
Novan's shares were split on a 1:10 basis on 25 May 2021. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Novan shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Novan shares which in turn could have impacted Novan's share price.
Over the last 12 months, Novan's shares have ranged in value from as little as $0.0201 up to $0.0351. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Novan's is -0.0434. This would suggest that Novan's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Novan has bucked the trend.
Novan, Inc. , a medical dermatology company, focuses on developing and commercializing therapeutic products for skin diseases. Its clinical stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete's foot and fungal nail infections; and SB414, a topical cream-based gel product candidate for the treatment of inflammatory skin diseases. The company develops SB207, an anti-viral product candidate for the treatment of external genital warts; WH602, a nitric oxide-containing intravaginal gel to treat high-risk human papilloma virus (HPV); WH504, a non-gel formulation product candidate to treat high-risk HPV; and SB019 for the treatment of SARS-CoV-2. Novan, Inc. has a license agreement with Sato Pharmaceutical Co. , Ltd.
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
These are the best day trading platforms, according to Finder’s comprehensive analysis.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
Compare the 5 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
What you need to know about investing in the leading indicator for the overall US stock market.
Check out the best-performing ETFs so far in 2024.